Home » FDA Awards Orphan Drug Status to Immunocore for Uveal Melanoma Candidate
FDA Awards Orphan Drug Status to Immunocore for Uveal Melanoma Candidate
U.K.-based Immunocore has nabbed orphan drug status from the FDA for IMCgp100, a candidate for the treatment of uveal melanoma.
There are currently no effective treatments on the market for the disease, which affects the eye and makes up roughly 3 percent of all melanomas. The treatment is currently in Phase 2a clinical trials.
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May